TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Anesthetic Technique for AV Fistulae Creation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21-70 years old~* Able to give informed consent~* Creation of first time AV fistula~* Possible 3 month follow up visit~* ASA-I-IV~Exclusion Criteria:~* BMI ≥40~* Repeated AV fistula creation,~* ASA -V,~* Allergic to local anesthetic agents,~* Significant lung and cardiac disease,~* Infection at the site of regional anesthesia,~* Pre-existing peripheral nerve damage,~* Significant bleeding disorders,

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Local anesthesia (Type: ACTIVE_COMPARATOR): None
- regional anesthesia (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient ≥18 years and \<90 years of age~* Classification of RA according to the ACR/EULAR 2010 criteria~* Persistent clinical remission as defined by the ACR/EULAR remission criteria for at least 6 months (documented at ≥2 visits)~* Written informed consent~* Current treatment with a single csDMARD or a combination of csDMARDs plus a stable dose and administration interval (for the last 6 months) of a TNF-alpha inhibitor~* No current systemic corticosteroid treatment (stopped for at least 4 weeks), no corticosteroid injection within 4 weeks~* Stable dose of NSAIDs for at least 1 week~Exclusion Criteria:~* • Current treatment with any investigational drug~* Current administration interval of the anti-TNF-alpha agent of \>11 weeks~* Complete destruction of any joint to be investigated by sonography~* Current RA-related vasculitis or other active systemic (i.e. extraarticular) RA- manifestation with the exception of rheumatoid nodules~* Initial arthritis manifestations before the age of 17 years~* Planned surgery within the study period or history of surgery of any of the joints to be investigated clinically or by sonography~* Current severe medical illness requiring hospitalization~* Active infection or active malignancy at screening or infection during the past 4 weeks requiring (even temporary) discontinuation of the anti-TNF-alpha agent~* Pregnancy or lactation~* Inability of the patient to follow the protocol~* Current treatment with Rituximab (MabThera®)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- single arm ( bDMARD withdrawal ) (Type: EXPERIMENTAL): single arm (bDMARD withdrawal)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficient Anterior Shoulder Ultrasound Reduction Multicenter Prospective Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who are 18 years of age or older; and~2. Present to the VCU Emergency Department; and~3. Have clinical signs of uncomplicated shoulder dislocation; and~4. Agree to participation in the study; and~5. Provides a written consent to be included in the study.~Exclusion Criteria:~1. Patients who have a level 1 or 2 trauma activation, and/or;~2. Patients who are pregnant, incarcerated, or unable to consent, and/or;~3. Patients who have a past medical history of shoulder replacement in dislocated shoulder; and/or~4. Provider Discretion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- X-Ray (Type: ACTIVE_COMPARATOR): None
- Ultrasound (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Follow-up of Ohio State University Medical Center (OSUMC) Bariatric Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult~* Treated by OSUMC physicians for obesity~* Informed Consent~Exclusion Criteria:~* Informed consent not given

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing One-stage With Two-stage Basilic Vein Transposition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic renal failure on hemodialysis~* chronic renal failure with anticipated hemodialysis~Exclusion Criteria:~* Patient unwillingness, not consenting~* Cephalic vein options~* Basilic vein less than 2.5 mm~* Basilic vein with intrinsic lesions, unsuitable for use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- One-stage transposition of the basilic vein (Type: PLACEBO_COMPARATOR): One-stage transposition of the basilic vein
- Two-stage transposition of the basilic vein (Type: EXPERIMENTAL): Two-stage transposition of the basilic vein

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Analysis of Tokuhashi Score

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients diagnosed with any form of spinal metastases, whether symptomatic or not, regardless of tumor biology, and seen by a physician in the Department of Orthopedic Surgery, will be asked to enter this trial.~* Must be a patient of our practice~Exclusion Criteria:~* There is no exclusion criteria

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen for COVID-19 Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~In order to be eligible to participate in this study, an individual must meet all of the following criteria:~1. Male or female, age \> 18 years~2. Positive COVID 19 test~3. Respiratory compromise defined by SpO2 \<93%~4. Ability to sign informed consent~Exclusion Criteria:~An individual who meets any of the following criteria will be excluded from participation in this study:~1. Pregnancy~2. Untreated Pneumothorax

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperbaric oxygen therapy (HBOT) (Type: EXPERIMENTAL): None
- Standard of Care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hemoglobin less than 11 g/dl in the first trimester or less than 10.5 g/dl in the second trimester~* Microcytic anemia~* Singleton gestation in the first or second trimester~Exclusion Criteria:~* Malabsorptive disorder or history of restrictive or malabsorptive gastric surgery~* Known diagnosis of anemia other than iron deficiency (thalassemia, macrocytic, sickle cell, etc.)~* History of cardiopulmonary disease~* Severe anemia requiring parental infusion or transfusion of blood products

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Daily iron supplementation (Type: ACTIVE_COMPARATOR): Oral ferrous sulfate, 325 mg, take once daily
- Alternate day iron supplementation (Type: EXPERIMENTAL): Oral ferrous sulfated, 650mg, taken once daily every other day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imiquimod Treatment of CIN Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* newly diagnosed high grade CIN lesions (CIN 2-3), histologically confirmed~* age 18 years or older~Exclusion criteria:~* immunodeficiency~* pregnancy or lactation~* legally incapability~* history of histologically conformed high-grade CIN

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Imiquimod treatment arm (Type: EXPERIMENTAL): Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
- Standard treatment arm (Type: ACTIVE_COMPARATOR): Large loop excision of the transformation zone (LLETZ) will be performed in this group, as standard treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RCT of Efficacy and Safety of Sedation Compared to General Anesthesia for ERCP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with scheduled therapeutic ERCP~* Written informed consent for the study protocol obtained from the patient or his/her legal representative~* Anaesthetist available for the procedure~Exclusion Criteria:~* Mechanically ventilated patients before the procedure~* Baseline oxyhemoglobin saturation \< 90%~* Baseline systolic blood pressure \< 90 mm Hg~* American Society of Anaesthesiologists (ASA) physical score 5 (Table 1)~* Age \< 18 years~* Pregnancy~* Emergency procedure~* Absence of fasting ≥ 6 hours for solids and ≥ 2 hours for clear liquids~* Contraindication to any study drug~* Short, thick neck or trismus that may complicate airway rescue~* Previous documented difficult airway intubation~* Obstructive sleep apnea~* Severe swallowing disorders with documented broncho-aspiration~* Bowel obstruction~* Inclusion in the present protocol during the 30 preceding days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deep Sedation (Type: ACTIVE_COMPARATOR): Remifentanil 1ng/ml throughout the procedure. Propofol administration starts at an initial (estimated plasma) target concentration of 1,5 microg/ml.~Propofol administration is adjusted to level 1 or 2 on the modified observer's assessment of alertness/sedation scale. The propofol infusion will be increased stepwise by 0,5 microg/ml every 1 minute until loss of consciousness. Propofol is continued while maintaining spontaneous ventilation without assistance and systolic blood pressure ≥ 60 % of baseline systolic blood pressure.
- General Anaesthesia (Type: ACTIVE_COMPARATOR): General anesthesia will be induced with target controlled infusion (TCI) of propofol and remifentanil as in the group deep sedation.~Suxamethonium (succinylcholine) will be used to facilitate intubation. Endotracheal tube balloon pressure will be controlled during the procedure. Ventilation will be assisted using 40% oxygen in air mixture and mechanically controlled using an anaesthetic ventilator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Running Study for Runners With Chronic Knee Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Presence of patellofemoral pain~2. No history of any cardiovascular issues.~3. Currently running as part of training program~Exclusion Criteria:~1. No patellofemoral pain present.~2. Not currently running as part of training program~3. Other lower extremity pain and/or injury that interferes with ability to run.~4. Pregnant~5. Not in the selected age ranges~6. Presence of cardiovascular or cardiopulmonary diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Runners are switched from a rearfoot strike running pattern to a forefoot strike running pattern.
- Control (Type: NO_INTERVENTION): Runners continue to use their normal rearfoot strike running pattern with no intervention in place.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Compression Glove to Prevent Complications After Distal Radius Fractures: a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Between the ages of 18-85~* Patients with unstable unilateral distal radius fractures (requiring surgical stabilization)~Exclusion Criteria:~* Pre-existing cases of carpal tunnel syndrome and/or complex regional pain syndrome~* Nerve or tendon laceration~* Decompression of carpal tunnel concomitant with surgical stabilization~* Additional fractures, including carpal fractures, more proximal fractures of the radius, and finger injuries will be excluded from the study (Ulnar styloid and ulnar head and neck fractures will be included)~* Uncontrolled rheumatoid arthritis patients~* Bilateral fractures~* Unable or unwilling to provide written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Compression glove (Type: EXPERIMENTAL): Patients in this group have a compression glove incorporated into their splint for 2 weeks post-op, and wear a glove underneath their cast for 3 weeks. The patient then wears the glove at night after cast removal.
- Control (Type: NO_INTERVENTION): Patients in this group undergo standard recovery procedures. This includes a splint worn for 2 weeks post-op, followed by a short arm cast worn for the next 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Seizure Therapy for Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. DSM-5 diagnosis of schizophrenia;~2. convulsive therapy clinically indicated, such as severe psychomotor excitement or retardation, attempts of suicide, being highly aggressive, pharmacotherapy intolerance, and ineffectiveness of antipsychotics;~3. the positive and negative syndrome scale (PANSS)\[20\] score ≥ 60;~4. informed consent in written form.~Exclusion Criteria:~1. diagnosis of other mental disorders;~2. severe physical diseases, such as stroke, heart failure, liver failure, neoplasm, and immune deficiency;~3. present with a laboratory abnormality that could impact on efficacy of treatments or safety of participants;~4. failure to respond to an adequate trial of ECT lifetime;~5. are pregnant or intend to get pregnant during the study;~6. other conditions that investigators consider to be inappropriate to participate in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- magnetic seizure therapy (Type: EXPERIMENTAL): 10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
- electroconvulsive therapy (Type: ACTIVE_COMPARATOR): 10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Art in Improving Outcomes in Participants Undergo Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulant inpatients that will stay for at least 2 days postoperatively and do not require continuous monitoring~* All races and ethnic groups are eligible for this study~Exclusion Criteria:~* Patients with altered mental status, psychiatric illness, debilitating pain, blind patients, or those who require continuous monitoring postoperatively will be excluded from the study~* Adult unable to consent, individuals who are not yet adults, pregnant women or prisoners

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (art sessions) (Type: EXPERIMENTAL): Participants attend at least 1 session of viewing art pieces over 15 minutes every day for 2 years.
- Arm II (standard of care) (Type: ACTIVE_COMPARATOR): Participants receive standard of care for 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Allergic rhinitis symptoms during the pollen season preceding the study, confirmed by SPT (prick tests) and/or a positive specific IgE CAP test for birch pollen (class I minimum)~* Positive SPT to Bet v 1 (prick tests), negative SPT to AllerT~Exclusion Criteria:~* received immunotherapy against any allergen within 3 years before the start of the study.~* symptomatic to perennial allergens or active seasonal allergy during the trial.~* non controlled asthma (peak flow lower than 30% of predicted value).~* history of any severe medical condition able to influence the course of the study~* Any confirmed or suspected immunodeficiency condition, including human immunodeficiency virus (HIV) infection and asplenia.~* Subjects under immunosuppressive medication.~* Pregnant or lactating women or women willing or intending to become pregnant during the study.~* Any other significant finding which, in the opinion of the investigator, would increase the risk of having an adverse outcome from participating in this protocol or of dropping out of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- AllerT SC (Type: EXPERIMENTAL): AllerT subcutaneous injections
- Placebo SC (Type: PLACEBO_COMPARATOR): placebo subcutaneous injections
- AllerT ID (Type: EXPERIMENTAL): AllerT intra-dermal injections
- Placebo ID (Type: PLACEBO_COMPARATOR): placebo intra-dermal injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Community Primary Care Providers to Implement and Disseminate Cancer Prevention Interventions for Latino Populations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* New York State registered family practitioners and internal medicine physicians~* Minimum one half of their patients are Latino (provider self-reported)~* Currently practice in a small clinical setting (defined by no more than 5 providers) including community clinics, and/or private practice in Queens, Brooklyn, Bron and Staten Island, New York~* No active affiliation with a major hospital or academic institution.~Exclusion Criteria:~* Practicing medicine for less than 2 years~* Practicing in a setting where no health insurance is accepted

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Primary Care Providers (Type: None): Conduct and analyze in-depth, semi-structured interviews with community-based primary care providers serving large Latino populations and Form a community-based participatory committee.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues